Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8525050 | Biomedicine & Pharmacotherapy | 2018 | 8 Pages |
Abstract
Numerous antitumor therapies have been developed based on the differences in cells' metabolisms. Regarding the important role of arginine (Arg) in the regulation of multiple metabolic and signaling pathways, its deprivation has been proposed as a good strategy for tumor regression in tumors with defected Arg metabolic enzymes like argininosuccinate synthase 1 (ASS1). However, modulatory effect of Arg on various cancers is also a controversial issue. Therefore, this review article intends to address some of the challenges faced by Arg deprivation method as well as Arg administration for cancer therapy.
Keywords
OXPHOSHIF-1αLC3GLNASNMDSCsNOSOTCOrnithine decarboxylaseODCTAMsTCAMMP2/9AMPKNF-κBADCTGF-βASLASS1AMP-activated protein kinaseargininosuccinate lyaseCTLsECsERK1/2ADIROSArginineArginasearginine decarboxylasearginine deiminaseArgininosuccinate synthase 1AsparagineAIFArgtricarboxylic acidOrnithine aminotransferaseinterleukinSERtransforming growth factor beta 1Ornithine transcarbamylaseTumor associated macrophagesOatlight chain 3CancerSerinecytotoxic T cellsMyeloid-derived suppressor cellsEndothelial cellsapoptosis-inducing factorhypoxia inducible factor 1αVascular endothelial growth factorVascular Endothelial Growth Factor (VEGF)nuclear factor kappa BOxidative phosphorylationmajor histocompatibility complexMHCNitric oxidenitric oxide synthaseextracellular signal-regulated protein kinases 1 and 2glutamineReactive oxygen species
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Mozhgan Jahani, Fatemeh Noroznezhad, Kamran Mansouri,